# PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

> **NCT01248494** · PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 72 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** BEZ235
- **DRUG:** BKM 120
- **DRUG:** Letrozole
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01248494
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-12
- **Final completion:** 2016-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248494, "PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01248494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*